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ABSTRACT
A 3-year retrospective study evaluated the effect-
iveness and safety of cefepime plus a ﬂuoroqui-
nolone for treating bone and joint infections
caused by Gram-negative bacilli (GNB) in 28
patients. Intra-operative cultures yielded primar-
ily Pseudomonas spp. and Enterobacter cloacae. Full
recovery (cure) was observed in 79% of patients.
There were no serious adverse effects and no
resistant organisms were isolated. The results of
the study conﬁrmed the safety and effectiveness
of cefepime combined with a ﬂuoroquinolone for
the treatment of bone and joint infections caused
by Gram-negative bacilli.
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Numerous therapeutic approaches to the treat-
ment of bone and joint infections caused by
Gram-negative bacilli (GNB) have been described
[1–6]. Several reports [7–10] have demonstrated
that ﬂuoroquinolones inhibit the adherence of
GNB to implanted devices. In addition, it has
been reported [7,10,11] that ﬂuoroquinolones
have activity against non-growing cells of Pseu-
domonas, and that they are able to eradicate
bioﬁlms in vitro [9]. Breilh et al. [12] reported that
cefepime diffuses readily into bone. The activity
of cefepime against GNB, including many dere-
pressed mutants [7,13], and the synergic activity
of new cefepime ⁄ﬂuoroquinolone combinations
against some GNB [13], makes cefepime an
interesting choice for the treatment of bone and
joint infections. This retrospective study evalu-
ated the safety and the efﬁcacy of cefepime ⁄ﬂuor-
oquinolone combinations for the treatment of
bone and joint infections. Results are reported
only for those patients who were followed for
more than 2 years.
During the 3-year period January 1999 to
December 2001, the medical charts of patients
treated by the Orthopaedic Surgery Service, Lille,
France, for bone and joint infections associated
with GNB were reviewed. Clinical criteria for
inclusion were fever >38C and inﬂammation in
the surgical area. Biological criteria included an
erythrocyte sedimentation rate >50 mm ⁄h and
elevated C-reactive protein (>10 mg ⁄L). Radiolo-
gical criteria were pseudarthrosis, a loosening
prosthesis or osteomyelitis. Antibiotics were dis-
continued 15–30 days before obtaining wound
cultures. In case of sepsis, samples were collected
immediately. At least three samples were taken
intra-operatively. Blood specimens were drawn
from all febrile patients. Superﬁcial samples were
not used. Plates incubated at 37C were examined
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every day for 7 days. Microbial isolates were
identiﬁed using standard techniques [14], and
susceptibility results were interpreted according
to the recommendations of the Comite´ de l’Anti-
biogramme de la Socie´te´ Franc¸aise de Microbi-
ologie [15]. Serum levels of cefepime were
assessed by HPLC. Peak serum concentrations
(Cmax) were obtained following intravenous infu-
sion for 30 min. The trough level (Cmin) was
measured 15 min before infusion. Cefepime was
administered intravenously twice daily (2 g ⁄ 12 h)
for a total of 4 weeks, adjusted according to renal
function. For the ﬁrst 5 days, a ﬂuoroquinolone
was administered intravenously, followed by oral
administration (oﬂoxacin 200 mg · 3 ⁄day or
ciproﬂoxacin 500–750 mg · 2 ⁄day for Pseudomon-
as spp.). The duration of oral treatment with a
ﬂuoroquinolone was dictated by the type of
device infection, with antibiotic treatment for 6
and 9 months for hip and knee prostheses,
respectively [16], and for 3 months for osteosyn-
thesis devices. When mixed infections were diag-
nosed, additional appropriate antibiotics were
added to the cefepime ⁄ﬂuoroquinolone combina-
tion. Surgical treatment was planned with regard
to the delay in the appearance of infection
following joint arthroplasty, the state of fracture
healing and implant stability, and the general
condition of the patient [11,16]. Cure was deﬁned
as an absence of clinical, biological and radiolo-
gical evidence of infection following all post-op-
erative treatment. Failure was deﬁned as any
other outcome. In cases of treatment failure,
patient compliance was assessed and pre-opera-
tive samples were taken from patients who
underwent a second surgical procedure and
appropriate treatment.
Twenty-eight patients (23 males, ﬁve females;
mean age 47 (range 22–90) years) with bone and
joint infection caused by GNB were included in
the study (Table 1). Underlying co-morbid condi-
tions included diabetes mellitus (n = 2), steroid
therapy (n = 5), rheumatoid arthritis (n = 1),
malignancy (n = 1), chronic alcohol abuse (n = 5)
and hypoalbuminaemia (n = 2). Eleven (39%)
patients had no inﬂammatory syndrome. The
others had a mean leukocyte count of 11.8
(range 4.5–18.5) g ⁄L, mean C-reactive protein of
120 (range 5–250) mg ⁄L, and a mean erythrocyte
sedimentation rate of 86 (range 17–150) mm ⁄h.
Table 1. Characteristics of 28 patients with bone and joint infections caused by Gram-negative bacilli
No. Localisation
Clinical
signs
Radiological
signs
Type of
infection
Delay
(month)
Surgical
treatment
Outcome
(reason for
failure)
1 Knee Fever, Fi,I IF device 7 Debridement Cure
2 Femur Fever, I,Fi IF device < 1 Debridement Cure
3 Tibia Fever, P,Fi,I IF device < 1 Debridement Cure
4 Ankle Fever, I Pseudoarthrosis IF device 20 Removal, debridement and
bone graft and external ﬁxateur
Cure
5 Tibia Fever, P,Fi Pseudoarthrosis IF device 3 Removal device and external ﬁxateur Failure (MRSA)
6 Femur Fi,I IF device < 1 Debridement Cure
7 Foot Fever, P,Fi,I IF device < 1 Debridement Cure
8 Foot Fever, I Chronic OM Amputationb Cure
9 Hip Fever, P,Fi Looseness Prosthesis 78 Debridement Dieda
10 Hip Fi,I Prosthesis < 1 Removal prosthesis in one stage Cure
11 Hip Fi, luxation Repetitive luxation Prosthesis 46 Removal prosthesis in two stages Cure
12 Knee Fever, P,I Looseness Prosthesis 21 Arthrodesis Cure
13 Tibia Fever, P,Fi,I IF device 2 Removal devices and external ﬁxateur Failure (Pseudomonas spp.)
14 Ankle Fi,I Pseudoarthrosis IF device 33 Removal devices and external ﬁxateur Lost to follow-up
15 Foot Fi,P Pseudoarthrosis IF device 213 Debridement Failure (Peptostreptococcus)
16 Ankle Fi Pseudoarthrosis IF device 18 Removal devices and external ﬁxateur Cure
17 Knee Fever, P Chronic OM Debridement Cure
18 Femur Fever, Fi,I IF device 6 Debridement Lost to follow-up
19 Foot P,Fi Chronic OM Debridement Lost to follow-up
20 Tibia Fi IF device 146 Debridement Failure (CNS, Bacteroides fragilis)
21 Tibia Fi Chronic OM Debridement Cure
22 Knee Fever, P Prosthesis < 1 Debridement Cure
23 Femur Fi Chronic OM Debridement Cure
24 Radius P,Fi, I Pseudoarthrosis IF device 10 Removal devices and bone graft Failure (B. fragilis)
25 Sternum Fi,I IF device 24 Removal devices Cure
26 Knee Fi,P,I Pseudoarthrosis IF device 36 Amputationb Cure
27 Femur P, fever IF device 1 Debridement Cure
28 Sternum Fi IF device 2 Debridement Cure
Clinical signs: fever >38C; I, local inﬂammatory; Fi, ﬁstula; P, pain.
Type of infection: IF device; internal ﬁxation device; Chronic OM; chronic osteomyelitis.
Microbiology: MRSA, methicillin-resistant Staphylococcus aureus; CNS, coagulase-negative Staphylococcus.
aMyocardial infarction unrelated to antibiotic treatment.
bThese patients needed an amputation because of bone destruction. The bone biopsy conﬁrmed osteomyelitis.
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Culture and susceptibility results for 28 intra-
operative samples are shown in Table 2. Six
patients were monitored for cefepime levels: the
Cmin was 4.02 (range 1.6–6.6) mg ⁄L and the
Cmax was 62.15 (range 32.3–86.6) mg ⁄L. Eryt-
hema or pain at the site of injection, alteration
of taste, and diarrhoea were reported by four
patients, but none discontinued the treatment.
Twenty-four patients were available for ﬁnal
review (Table 1), of whom 19 (79%) were cured
(8 ⁄ 12 treated with their implants in situ; 7 ⁄ 11
treated with device removed; four with osteo-
myelitis). The three patients lost to follow-up
were without known recurrence of infection, but
respective follow-up periods were for 1 year
only. Failure was observed in ﬁve patients at a
mean of 8 (range 1–16) months following
surgery. Each of these patients underwent fur-
ther surgery and additional treatment because
of recurrent sepsis.
A number of difﬁculties occur when treating
bone and joint infections caused by GNB. Only a
limited number of experimental models [17–19]
have been described, although these have dem-
onstrated high bone concentrations of ﬂuoroqu-
inolones above the MICs for most GNB [1–3,6–
8,13,17–19]. Further, randomised controlled clin-
ical trials are hampered by the fact that only
large institutions have sufﬁcient patients for such
studies, and successful treatment requires a
follow-up period of 1–2 years [1–6,11,16]. Several
trials with ceftazidime ⁄ﬂuoroquinolone [1,2,4], a
ﬂuoroquinolone alone [3,5] or imipenem-cilasta-
tin [6] have been reported, with degrees of
success. In the present study, the Cmin of cefep-
ime compared favourably with published reports
[19], and was generally greater than the MICs for
most GNB. Because of these antibiotic properties,
a cefepime ⁄ﬂuoroquinolone combination was
used for the ﬁrst month to dramatically decrease
the number of bacteria associated with surgery,
to limit the risk of emergence of drug-resistant
mutants, and thus to permit continuation with
ﬂuoroqinolone monotherapy. The period of treat-
ment was quite long, based on the results of a
study by Drancourt et al. [20], but no random-
Table 2. Susceptibilities of Gram-negative bacilli (GNB) isolated from 28 patients with bone and joint infections
No. Intra-operative samples
Susceptibility of GNB
PIP TZP CAZ CFP IMP ATM OFX CIP GM
1 Pseudomonas spp. R R R S R R R S I
2 Enterobacter cloacae, MSSAa S S S S S S S S S
3 Pseudomonas spp. S S S S S S S S S
4 E. cloacae S S S S S S S S S
5 Acinetobacter baumannii R S R S R R R S R
6 E. cloacae R R R S S R I S S
7 Pseudomonas spp. S S S S S S S S S
8 Pseudomonas spp., CNSa S S S S S S R S S
9 Serratia marcescens R I S S S S R S S
10 E. cloacae, MSSAa I S S S S S S S S
11 A. baumannii I S S S S R R S R
12 Pseudomonas spp., MRSAa S S S S S S S S S
13 E. cloacae S S S S S S S S S
14 Pseudomonas spp. R S S S S S S S S
15 Pseudomonas spp. S S S S S S S S S
16 Stenotrophomonas maltophilia R R S S R R S S
E. cloacae, CNSa S S S S S S S S S
17 Pseudomonas spp. S S S S I S R I R
18 E. cloacae, CNS, Streptococcus spp.a R R R S S R S S S
19 Pseudomonas spp. S S S S S S S S S
20 E. cloacae, MSSAa S S S S S S S S S
Klebsiella oxytoca S S S S S S S S S
21 Pseudomonas spp., CNSa S S S S S S S S S
22 Pseudomonas spp. S S R S S S I S S
23 E. cloacae R R R S S S S S S
24 E. cloacae R R R S S R I S S
25 Enterobacter aerogenes R R R S I R R I R
26 Pseudomonas spp., Corynebacterium spp.a R S S S S S S S S
27 Steno. maltophilia, MRSAa R R S S R R S S
Pseudomonas spp. R S S S S S S S S
28 Serr. marcescens S S S S S S I S R
MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant S. aureus.
CNS, coagulase-negative Staphylococcus spp.
aWhen mixed microorganisms were isolated, appropriate treatment was added to cefepime ⁄ﬂuoroquinolone.
CNS and corynebacteria were isolated from three intra-operative samples and were considered pathogens.
PIP, piperacillin; TZP, piperacillin-tazobactam; CAZ, ceftazidime; CFP, cefepime; IMP, imipenem; AZT, aztreonam; OFX, oﬂoxacin; CIP, ciproﬂoxacin; GM, gentamicin.
S, susceptible; I, intermediately-resistant; R, resistant.
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ised study has determined the optimal length of
treatment for bone and joint infections. No
patients were obliged to stop treatment in the
present study, and no resistant strains emerged
during treatment.
In conclusion, cefepime combined with a ﬂuor-
oquinolone appears to be a safe and effective
treatment for bone and joint infections caused by
GNB, but further studies are required to substan-
tiate these ﬁndings.
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